NEW YORK, August 1, 2016 /PRNewswire/ --
The Biotech industry is where investors come out either short or confidently strong. Following its fall in September 2015, the industry is now signaling a pullback, suggesting to the investor community that buying opportunities are available. Additionally, the sector finished on a solid note in July 2016, up 10%. Today, Stock-Callers.com has the following equities on its radar for further assessment: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Aduro BioTech Inc. (NASDAQ: ADRO), and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). These stocks research reports can be downloaded now by simply registering for free at:
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc's shares finished 0.82% higher at $97.00 with a total volume of 1.01 million shares traded. The stock has gained 14.12% in the last month and 15.01% in the previous three months. The Company's shares are trading above their 50-day moving average by 8.40%. Moreover, shares of Vertex Pharmaceuticals, which engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases, have a Relative Strength Index (RSI) of 64.25.
On July 06th, 2016, Vertex Pharmaceuticals and Moderna Therapeutics announced that they have entered into an exclusive research collaboration and licensing agreement aimed at the discovery and development of messenger Ribonucleic Acid (mRNA) Therapeutics™ for the treatment of cystic fibrosis (CF). Under the terms of the collaboration, Vertex and Moderna will conduct exclusive research, development and commercialization activities to advance mRNA Therapeutics that aim to enable cells of people with CF to produce functional CFTR proteins in the lungs. Vertex will pay Moderna $20 million in cash as part of its upfront commitment to the collaboration. Vertex will also make a $20 million investment in Moderna in the form of a convertible note that will convert to equity. The investment will provide Vertex with an ownership stake in Moderna. Your complete research report on VRTX can be retrieved for free at:
Shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. ended Friday's session 3.70% higher at $1.68 and with a total volume of 1.25 million shares traded. The stock has advanced 21.74% in the last month. Shares of the Company, which discovers, develops, and delivers medicines to patients with difficult-to-treat diseases, are trading 39.25% below their 50-day moving average. Moreover, Infinity Pharmaceuticals' stock has an RSI of 37.41.
On June 28th, 2016, Infinity Pharmaceuticals announced that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop and commercialize duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The companies had been in discussions regarding a potential restructuring of the partnership but were unable to find a mutually attractive financial structure for continuation of the collaboration. With the termination of this agreement, Infinity has regained worldwide rights to duvelisib and neither Infinity nor AbbVie have future financial obligations to the other party. INFI free report is just a click away at:
Berkeley, California-based Aduro BioTech Inc.'s shares dropped 1.61%, closing the session at $14.68. A total volume of 304,125 shares was traded. The stock has surged 33.70% in the last one month and 13.36% over the previous three months. The Company's shares are trading 21.84% above their 50-day moving average. Additionally, shares of Aduro BioTech, which focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases, have an RSI of 66.94. Sign up for your complimentary research report on ADRO at:
On Friday, shares in Milton, Canada headquartered Aralez Pharmaceuticals Inc. closed the session 0.85% lower at $3.50 and with a total volume of 376,141 shares traded. The stock has gained 3.86% in the last month. The Company's shares are trading below their 50-day moving average by 3.55%. Furthermore, shares of Aralez Pharmaceuticals, which engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain/inflammation, and dermatology areas; and gastrointestinal, women's health, and other nonprescription products, have an RSI of 43.64.
On July 26th, 2016, Aralez Pharmaceuticals announced that it will report its Q2 2016 financial results on August 9th, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 11:00 a.m. ET on the same date to discuss the financial results and recent highlights. Register for free on Stock-Callers.com and download the latest research report on ARLZ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA